

# Electrical stimulation for lung muscle rehabilitation in patients with COVID-19

<b>Submission date</b> 10/09/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 21/10/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 31/03/2022	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Approximately 15% of patients with SARS-CoV-2 (COVID-19) infection develop acute interstitial pneumonia which requires hospitalization and oxygen administration. Complications in severe cases of COVID-19 include acute respiratory distress syndrome (ARDS). Research results confirm that older age and D-dimer concentrations > 1 µg/L on admission to hospital are associated with higher mortality.

Currently, there are no clear guidelines on how to conduct pulmonary rehabilitation in patients with COVID-19. Studies conducted in recent years have shown that the use of physical training in patients with chronic interstitial lung diseases is safe and brings numerous benefits like improved the quality of life, physical efficiency and lowered levels of pro-inflammatory cytokines. On the other hand, prolonged inactivity leads to skeletal muscle atrophy, exercise intolerance, venous thrombosis, pulmonary embolism and pressure ulcers.

But what if a COVID-19 patient is unable to exercise due to experiencing discomfort from shortness of breath and dyspnoea?

It seems that an alternative to physical training may be neuromuscular electrostimulation (NMES) of the skeletal muscles of the lower extremities. NMES is a safe form of skeletal muscle training. It can be used in patients with moderate to severe dyspnoea in COPD, and even in patients undergoing respiratory therapy. Lower limb muscle electrostimulation increases the muscle strength, improves physical performance and quality of life.

From the above argumentation, it seems justified to undertake research aimed at assessing the use of electrostimulation of the skeletal muscles of the lower extremities in the rehabilitation of patients with COVID-19.

### Who can participate?

Adults suffering from COVID-19 interstitial pneumonia.

### What does the study involve?

The patients will be divided into 2 comparative groups – one experimental group and one control group. Patients in the experimental group will receive NMES electrical stimulation in addition to the standard treatment. Patients in control groups will receive standard treatment according to current medical guidelines.

What are the possible benefits and risks of participating?

NMES in combination with the conventional COVID-19 treatment will contribute to a better improvement in the physical performance and quality of life of COVID-19 patients. NMES in patients with COVID-19 will result in a greater reduction in inflammation.

Possible risks are allergic reactions to the electrodes, muscle pain or paraesthesia and damage to the skin by electrodes.

Where is the study run from?

Academy of Physical Education in Katowice (Poland).

St. Elizabeths Hospital in Katowice (Poland).

When is the study starting and how long is it expected to run for?

November 2020 to January 2022

Who is funding the study?

The Academy of Physical Education in Katowice (Poland).

Who is the main contact?

Laura Piejko

[l.piejko@awf.katowice.pl](mailto:l.piejko@awf.katowice.pl)

## Contact information

### Type(s)

Scientific

### Contact name

Dr Laura Piejko

### ORCID ID

<http://orcid.org/0000-0002-5338-1842>

### Contact details

The Academy of Physical Education in Katowice

72a Mikołowska Street

Katowice

Poland

40-065

+48 (0)32 207 51 01

[l.piejko@awf.katowice.pl](mailto:l.piejko@awf.katowice.pl)

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

### ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

Nil known

# Study information

## Scientific Title

Neuromuscular electrostimulation (NMES) of skeletal muscles in the rehabilitation of patients with COVID-19 interstitial pneumonia

## Study objectives

When a patient with COVID-19 is unable to exercise due to the perceived discomfort of shortness of breath, an alternative to physical training may be neuromuscular electrostimulation (NMES) of the skeletal muscles of the lower extremities.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 17/12/2020, Bioethics Commission for Scientific Research at The Jerzy Kukuczka Academy of Physical Education in Katowice (Mikołowska 72a Street, 40-065 Katowice, Poland; +48 (0)322075152; komisjabioetyczna@awf.katowice.pl), ref: 4/2020

## Study design

Interventional randomized controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

## Health condition(s) or problem(s) studied

COVID-19 interstitial pneumonia

## Interventions

The study will include patients with COVID-19 interstitial pneumonia documented with positive SARS-CoV-2 RT-PCR test result.

Single-center interventional randomized controlled trial.

The intervention will consist of 2 stages.

In the first stage, after tests completion (chest CT scan, gasometry measured with the SpO<sub>2</sub> pulse oximeter, ECG, anthropometric indicators and laboratory tests ) and meeting the inclusion criteria, patients will be qualified by the attending physician to participate in the experiment.

In the second stage, COVID-19 patients will be randomly assigned to one of two groups:

1/ In the first group NMES electrical stimulation will be conducted in 20 COVID-19 patients in addition to the standard treatment.

Quality of life will be tested with the Polish version of the CAT questionnaire. Each patient will be assessed also using the The MRC dyspnoea scale. The exercise tolerance and dyspnoea will be assessed according to the Borg scale.

Physical capacity will be assessed by selected ADL activities (e.g. sitting alone in bed with legs lowered, lifting both lower limbs separately at 30° and holding them in this position until tired, standing alone by bed, getting out of bed and sitting alone in a chair while standing by the bed, walking without help). The implementation of the above interventions will depend on the clinical condition of the patient and will be ordered by the attending physician.

Muscle electrostimulation (NMES) will be performed 5 times a week for 40 minutes under the supervision of a physiotherapist and will last for 3 weeks (15 sessions). NMES will be conducted on thigh muscles (20 mins) and calf muscles (20 mins) of both limbs. The electrodes will be placed on the proximal and distal ends of the muscle bellies. An biphasic symmetrical electrical current of 35 Hz frequency will be used. The pulse duration will be 0.3 ms. The intensity will be set up to achieve tetanic muscle contraction with 30-45% of the maximum muscle strength. The duration of the series of pulses (duration of contraction) will be 2 seconds and the duration of the pause between series of pulses (duration of the contraction) will be 4 seconds.

Neuromuscular electrostimulation of the skeletal muscles of the lower extremities will be performed with a portable dual-circuit electrotherapy device by Mettler Electronics Trio Stimulator. Square self-adhesive electrodes with dimensions of 5cm × 5cm will be used.

2/ The second group (control) will consist of 20 COVID-19 patients treated with the current medical guidelines.

After 15 days of hospitalization, anthropometric indices (body weight, BMI, adipose tissue mass) will be determined for each patient and a CT scan of the chest and gasometry (while resting) will be performed. 10 ml of blood will be taken from each of the examined patients to determine selected laboratory parameters such as morphology, ALAT, AST, CPK, and concentrations of CRP, TNF and sTNFR, IL-6, IL-10, fibrinogen and d-dimers). Quality of life will be tested with the Polish version of the CAT questionnaire. The exercise tolerance and dyspnoea will be assessed according to the Borg scale.

## **Intervention Type**

Device

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Electrotherapy device Trio Stim from Mettler Electronics

## **Primary outcome measure**

Quality of life in COVID-19 patients assessed with the Polish version of the CAT questionnaire at baseline and after treatment.

## **Secondary outcome measures**

1. Selected respiratory (gasometric) indicators measured by SpO2 pulse oximeter at baseline and after treatment.
2. Laboratory indicators (TNF, sTNFR1, IL-6, IL-10, d-dimers, CRP) measured by laboratory blood tests at baseline and after treatment.

## **Overall study start date**

30/11/2020

## **Completion date**

30/01/2022

# **Eligibility**

## **Key inclusion criteria**

1. COVID-19 (positive RT-PCR test and interstitial pneumonia observed in CT scan),
2. Clinically severe interstitial pneumonia with respiratory failure / pre ARDS (MEWS classification of 3-4 points),
3. <90-92% SpO2 at rest
4. Consent to participate in the study.

## **Participant type(s)**

Patient

## **Age group**

Adult

## **Sex**

Both

## **Target number of participants**

40

## **Key exclusion criteria**

1. Unstable ischemic heart disease,
2. Significant haemodynamic aortic stenosis,
3. Valve defects requiring surgical correction,
4. Complex ventricular arrhythmias,
5. Implantation of a cardiac pacemaker, cardioverter-defibrillator (ICD) and cardiac re-synchronizing pacemaker (CRT),
6. Acute myocarditis or pericarditis,
7. Uncontrolled hypertension,
8. End-stage renal disease and liver failure disease,
9. Lack of consent to participate in the study.

## **Date of first enrolment**

25/10/2021

## **Date of final enrolment**

16/01/2022

# Locations

## Countries of recruitment

Poland

## Study participating centre

**The Jerzy Kukuczka Academy of Physical Education in Katowice**

72a Mikołowska Street

Katowice

Poland

40-065

## Study participating centre

**St. Elizabeths Hospital in Katowice**

52 Warszawska Street

Katowice

Poland

40-008

# Sponsor information

## Organisation

Akademii Wychowania Fizycznego im. Jerzego Kukuczki w Katowicach

## Sponsor details

72a Mikołowska Street

Katowice

Poland

40-065

+48 (0)32 207 51 10

rektorat@awf.katowice.pl

## Sponsor type

University/education

## Website

<https://awf.katowice.pl/>

## ROR

<https://ror.org/05wtrdx73>

# Funder(s)

## Funder type

University/education

## Funder Name

Akademia Wychowania Fizycznego im. Jerzego Kukuczki w Katowicach

## Alternative Name(s)

The Jerzy Kukuczka Academy of Physical Education in Katowice, AWF Katowice

## Funding Body Type

Government organisation

## Funding Body Subtype

Universities (academic only)

## Location

Poland

# Results and Publications

## Publication and dissemination plan

Publication in a scientific journal is planned.

## Intention to publish date

01/01/2022

## Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

## IPD sharing plan summary

Data sharing statement to be made available at a later date